You are here: Industry Insights > nr-axSpA

News List

AbbVie seeks approval for upadacitinib to treat nr-axSpA pharmaceutical-business-review
January 10, 2022
Abbvie has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to obtain approvals...
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis pharmatimes
June 21, 2021
Novartis’ Cosentyx has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA).
Cosentyx Receives FDA Approval for New Indication americanpharmaceuticalreview
June 29, 2020
Novartis announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis pharmaceutical-business-review
June 22, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Cosentyx (secukinumab) to treat active non-radiographic axial spondyloarthritis (nr-axSpA).
Lilly bags expanded EU approval for Taltz pharmatimes
June 08, 2020
The European Medicines Agency has expanded the reach of Lilly's Taltz (ixekizumab) to include the treatment of adults with active ankylosing spondylitis and active non-radiographic axial spondyloarthritis (nr-axSpA).
Cosentyx Gains Fourth indication in EU for Axial Spondyloarthritis Spectrum americanpharmaceuticalreview
May 05, 2020
Novartis announced the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Lilly’s Taltz meets endpoints in Phase III study for nr-axSpA pharmaceutical-technology
April 24, 2019
Global pharmaceutical company Eli Lilly has announced top line results for Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA).